Target intelligence / Profile preview

Gamma-aminobutyric acid transporter (GAT)

Target
GAT
Molecular classification
Transporter, Neurotransmitter/sodium symporter, Solute carrier family 6 member
01

Overview

Gamma‐aminobutyric acid transporters are a family of membrane proteins responsible for the reuptake and regulation of the inhibitory neurotransmitter gamma‐aminobutyric acid (GABA) from the synaptic cleft. They belong to the solute carrier 6 family and function as sodium/chloride-dependent symporters. The main subtypes—GAT1, GAT2, and GAT3—are differentially expressed throughout neurons and glial cells in the brain. By controlling extracellular levels of GABA during both basal activity and synaptic transmission, these transporters play a critical role in maintaining inhibitory tone within neural circuits. Pharmacological inhibition—such as by tiagabine—is clinically exploited to treat epilepsy by enhancing synaptic inhibition through increased ambient levels of extracellular GABA. Structural studies reveal that these transporters have 12 transmembrane domains with key sites for substrate binding and inhibitor interaction.

Other names
GABA transporterGAT1 (SLC6A1)GAT2 (SLC6A13)GAT3 (SLC6A11)Betaine-GABA transporter (BGT1, SLC6A12)
02

Mechanism of action

Inhibition of GABA reuptake, increasing extracellular levels of inhibitory neurotransmitter; Modulation of synaptic inhibition by altering presynaptic and extrasynaptic GABA concentrations

03

Biological functions

Regulation of extracellular gamma-aminobutyric acid (GABA) concentrationSynaptic transmission modulationRecycling of inhibitory neurotransmitter in the central nervous system
04

Disease associations

Epilepsy and seizure disordersNeurodegenerative diseaseOther neurological disorders
05

Safety considerations

Risk of excessive CNS inhibition leading to sedation, confusion, or ataxia with potent inhibitors.Potential for drug interactions affecting seizure threshold.Off-target effects due to broad expression in CNS and peripheral tissues.
06

Interacting drugs

Tiagabine

3 more in the full profile.

07

Biomarkers

None specifically established for patient selection or efficacy monitoring; changes in cerebrospinal fluid or brain extracellular GABA may be used experimentally.

Beyond the preview

Go deeper on Gamma-aminobutyric acid transporter (GAT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gamma-aminobutyric acid transporter (GAT).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call